Dr. Steven Schuster, MD
Claim this profilePoudre Valley Hospital
Studies Colorectal Cancer
Studies Lung Cancer
14 reported clinical trials
33 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
RAS negative
PD-L1 positive
2Lung Cancer
Stage IV
Stage III
PD-L1 negative
Affiliated Hospitals
Clinical Trials Steven Schuster, MD is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: Pembrolizumab or, Pembrolizumab and carboplatin, or Pembrolizumab and cisplatin In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
Epoetin Alfa vs Luspatercept
for Myelodysplastic Syndrome
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Recruiting2 awards Phase 3
More about Steven Schuster, MD
Clinical Trial Related5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Steven Schuster, MD has experience with
- Nivolumab
- Carboplatin
- Pembrolizumab
- Epoetin Alfa
- Luspatercept
- Selinexor
Breakdown of trials Steven Schuster, MD has run
Colorectal Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Plasma Cell Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven Schuster, MD specialize in?
Steven Schuster, MD focuses on Colorectal Cancer and Lung Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are RAS negative.
Is Steven Schuster, MD currently recruiting for clinical trials?
Yes, Steven Schuster, MD is currently recruiting for 8 clinical trials in Fort Collins Colorado. If you're interested in participating, you should apply.
Are there any treatments that Steven Schuster, MD has studied deeply?
Yes, Steven Schuster, MD has studied treatments such as Nivolumab, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Steven Schuster, MD?
Apply for one of the trials that Steven Schuster, MD is conducting.
What is the office address of Steven Schuster, MD?
The office of Steven Schuster, MD is located at: Poudre Valley Hospital, Fort Collins, Colorado 80524 United States. This is the address for their practice at the Poudre Valley Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.